EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1

Harri A Järveläinen iD, Christian Schmithals, Maike von Harten, Bianca Kakoschky, Thomas J Vogl iD, Stephen Harris iD, Claire Henson, Gemma Bullen-Clerkson, Albrecht Piiper

International Journal of Molecular Sciences · 16.03.2023 · 24 (6) · 5700

DOI: 10.3390/ijms24065700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.03.2023. Verfasst von Harri A Järveläinen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, 00014 Helsinki, Finland. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid, Cend Therapeutics, DrugCendR Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CEND-1 (iRGD) is a bifunctional cyclic peptide that can modulate the solid tumour microenvironment, enhancing the delivery and therapeutic index of co-administered anti-cancer agents. This study explored CEND-1’s pharmacokinetic (PK) properties pre-clinically and clinically, and assessed CEND-1 distribution, tumour selectivity and duration of action in pre-clinical tumour models. Its PK properties were assessed after intravenous infusion of CEND-1 at various doses in animals (mice, rats, dogs and monkeys) and patients with metastatic pancreatic cancer. To assess tissue disposition, [3H]-CEND-1 radioligand was administered intravenously to mice bearing orthotopic 4T1 mammary carcinoma, followed by tissue measurement using quantitative whole-body autoradiography or quantitative radioactivity analysis. The duration of the tumour-penetrating effect of CEND-1 was evaluated by assessing tumour accumulation of Evans blue and gadolinium-based contrast agents in hepatocellular carcinoma (HCC) mouse models. The plasma half-life was approximately 25 min in mice and 2 h in patients following intravenous administration of CEND-1. [3H]-CEND-1 localised to the tumour and several healthy tissues shortly after administration but was cleared from most healthy tissues by 3 h. Despite the rapid systemic clearance, tumours retained significant [3H]-CEND-1 several hours post-administration. In mice with HCC, the tumour penetration activity remained elevated for at least 24 h after the injection of a single dose of CEND-1. These results indicate a favourable in vivo PK profile of CEND-1 and a specific and sustained tumour homing and tumour penetrability. Taken together, these data suggest that even single injections of CEND-1 may elicit long-lasting tumour PK improvements for co-administered anti-cancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsRatsMiceAnimalsDogsInfusions, IntravenousPeptidesTumor Microenvironment

Stichwörter der Autor:innen

CEND-1LSTA1certepetideiRGD peptidepharmacokineticsquantitative radioactivity analysis (QRA)quantitative whole-body autoradiography (QWBA)

Substanzen

Antineoplastic AgentsPeptides

Autor:innen und Institutionen

  • Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, 00014 Helsinki, Finland.
  • Department of Medicine 1, University Hospital Frankfurt, 60590 Frankfurt, Germany.
  • Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
  • Department of Metabolism, Pharmaron UK, Pegasus Way, Crown Business Park, Rushden, Northamptonshire NN10 6ER, UK.
  • German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

ORCID-Profile: Harri A Järveläinen, Thomas J Vogl, Stephen Harris

Förderung

  • German Cancer Aid
  • Cend Therapeutics
  • DrugCendR Australia
  • Deutsche Krebshilfe
  • Cend Therapeutics, Inc.
  • DrugCendR Australia Pty Ltd.

Zitieren

APA

Järveläinen, H. A., Schmithals, C., von Harten, M., Kakoschky, B., Vogl, T. J., Harris, S., Henson, C., Bullen-Clerkson, G., & Piiper, A. (2023). Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1. International Journal of Molecular Sciences, 24(6), 5700. https://doi.org/10.3390/ijms24065700

Vancouver

Järveläinen HA, Schmithals C, von Harten M, Kakoschky B, Vogl TJ, Harris S, et al. Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1. International Journal of Molecular Sciences. 2023;24(6):5700. doi:10.3390/ijms24065700

BibTeX
@article{Jrvelinen2023,
  author = {Järveläinen, Harri A and Schmithals, Christian and von Harten, Maike and Kakoschky, Bianca and Vogl, Thomas J and Harris, Stephen and Henson, Claire and Bullen-Clerkson, Gemma and Piiper, Albrecht},
  title = {Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5700},
  doi = {10.3390/ijms24065700}
}
Kostenlos starten →